Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

The circadian clock regulates RPE-mediated lactate transport via SLC16A1 (MCT1).

Milićević N, Ten Brink JB, Ten Asbroek ALMA, Bergen AA, Felder-Schmittbuhl MP.

Exp Eye Res. 2019 Oct 31;190:107861. doi: 10.1016/j.exer.2019.107861. [Epub ahead of print]

PMID:
31678436
2.

Does the circadian clock make RPE-mediated ion transport "tick" via SLC12A2 (NKCC1)?

Milićević N, Duursma A, Ten Asbroek ALMA, Felder-Schmittbuhl MP, Bergen AA.

Chronobiol Int. 2019 Nov;36(11):1592-1598. doi: 10.1080/07420528.2019.1653317. Epub 2019 Aug 23.

PMID:
31441327
3.

ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function.

de Majo M, Topp SD, Smith BN, Nishimura AL, Chen HJ, Gkazi AS, Miller J, Wong CH, Vance C, Baas F, Ten Asbroek ALMA, Kenna KP, Ticozzi N, Redondo AG, Esteban-Pérez J, Tiloca C, Verde F, Duga S, Morrison KE, Shaw PJ, Kirby J, Turner MR, Talbot K, Hardiman O, Glass JD, de Belleroche J, Gellera C, Ratti A, Al-Chalabi A, Brown RH, Silani V, Landers JE, Shaw CE.

Neurobiol Aging. 2018 Nov;71:266.e1-266.e10. doi: 10.1016/j.neurobiolaging.2018.06.015. Epub 2018 Jun 25.

4.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

5.

Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis.

Smith BN, Topp SD, Fallini C, Shibata H, Chen HJ, Troakes C, King A, Ticozzi N, Kenna KP, Soragia-Gkazi A, Miller JW, Sato A, Dias DM, Jeon M, Vance C, Wong CH, de Majo M, Kattuah W, Mitchell JC, Scotter EL, Parkin NW, Sapp PC, Nolan M, Nestor PJ, Simpson M, Weale M, Lek M, Baas F, Vianney de Jong JM, Ten Asbroek ALMA, Redondo AG, Esteban-Pérez J, Tiloca C, Verde F, Duga S, Leigh N, Pall H, Morrison KE, Al-Chalabi A, Shaw PJ, Kirby J, Turner MR, Talbot K, Hardiman O, Glass JD, De Belleroche J, Maki M, Moss SE, Miller C, Gellera C, Ratti A, Al-Sarraj S, Brown RH Jr, Silani V, Landers JE, Shaw CE.

Sci Transl Med. 2017 May 3;9(388). pii: eaad9157. doi: 10.1126/scitranslmed.aad9157.

6.

Oncogenic Properties of Candidate Oncogenes in Chromosome Region 17p11.2p12 in Human Osteosarcoma.

Both J, Wu T, Ten Asbroek AL, Baas F, Hulsebos TJ.

Cytogenet Genome Res. 2016;150(1):52-59. doi: 10.1159/000451046. Epub 2016 Nov 16.

PMID:
27846620
7.

NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.

Kenna KP, van Doormaal PT, Dekker AM, Ticozzi N, Kenna BJ, Diekstra FP, van Rheenen W, van Eijk KR, Jones AR, Keagle P, Shatunov A, Sproviero W, Smith BN, van Es MA, Topp SD, Kenna A, Miller JW, Fallini C, Tiloca C, McLaughlin RL, Vance C, Troakes C, Colombrita C, Mora G, Calvo A, Verde F, Al-Sarraj S, King A, Calini D, de Belleroche J, Baas F, van der Kooi AJ, de Visser M, Ten Asbroek AL, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Muñoz-Blanco JL, Strom TM, Meitinger T, Morrison KE; SLAGEN Consortium, Lauria G, Williams KL, Leigh PN, Nicholson GA, Blair IP, Leblond CS, Dion PA, Rouleau GA, Pall H, Shaw PJ, Turner MR, Talbot K, Taroni F, Boylan KB, Van Blitterswijk M, Rademakers R, Esteban-Pérez J, García-Redondo A, Van Damme P, Robberecht W, Chio A, Gellera C, Drepper C, Sendtner M, Ratti A, Glass JD, Mora JS, Basak NA, Hardiman O, Ludolph AC, Andersen PM, Weishaupt JH, Brown RH Jr, Al-Chalabi A, Silani V, Shaw CE, van den Berg LH, Veldink JH, Landers JE.

Nat Genet. 2016 Sep;48(9):1037-42. doi: 10.1038/ng.3626. Epub 2016 Jul 25.

8.

Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex.

Aronica E, Baas F, Iyer A, ten Asbroek AL, Morello G, Cavallaro S.

Neurobiol Dis. 2015 Feb;74:359-76. doi: 10.1016/j.nbd.2014.12.002. Epub 2014 Dec 10.

9.

Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS.

Smith BN, Ticozzi N, Fallini C, Gkazi AS, Topp S, Kenna KP, Scotter EL, Kost J, Keagle P, Miller JW, Calini D, Vance C, Danielson EW, Troakes C, Tiloca C, Al-Sarraj S, Lewis EA, King A, Colombrita C, Pensato V, Castellotti B, de Belleroche J, Baas F, ten Asbroek AL, Sapp PC, McKenna-Yasek D, McLaughlin RL, Polak M, Asress S, Esteban-Pérez J, Muñoz-Blanco JL, Simpson M; SLAGEN Consortium, van Rheenen W, Diekstra FP, Lauria G, Duga S, Corti S, Cereda C, Corrado L, Sorarù G, Morrison KE, Williams KL, Nicholson GA, Blair IP, Dion PA, Leblond CS, Rouleau GA, Hardiman O, Veldink JH, van den Berg LH, Al-Chalabi A, Pall H, Shaw PJ, Turner MR, Talbot K, Taroni F, García-Redondo A, Wu Z, Glass JD, Gellera C, Ratti A, Brown RH Jr, Silani V, Shaw CE, Landers JE.

Neuron. 2014 Oct 22;84(2):324-31. doi: 10.1016/j.neuron.2014.09.027. Epub 2014 Oct 22.

10.

Myelin and axon pathology in a long-term study of PMP22-overexpressing mice.

Verhamme C, King RH, ten Asbroek AL, Muddle JR, Nourallah M, Wolterman R, Baas F, van Schaik IN.

J Neuropathol Exp Neurol. 2011 May;70(5):386-98. doi: 10.1097/NEN.0b013e318217eba0.

PMID:
21487305
11.

Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.

Meyer zu Hörste G, Heidenreich H, Mausberg AK, Lehmann HC, ten Asbroek AL, Saavedra JT, Baas F, Hartung HP, Wiendl H, Kieseier BC.

Neurobiol Dis. 2010 Feb;37(2):483-90. doi: 10.1016/j.nbd.2009.11.006. Epub 2009 Nov 13.

PMID:
19914379
12.

Myelination competent conditionally immortalized mouse Schwann cells.

Saavedra JT, Wolterman RA, Baas F, ten Asbroek AL.

J Neurosci Methods. 2008 Sep 15;174(1):25-30. doi: 10.1016/j.jneumeth.2008.06.029. Epub 2008 Jul 6.

PMID:
18657574
13.

Comparison of Schwann cell and sciatic nerve transcriptomes indicates that mouse is a valid model for the human peripheral nervous system.

Ten Asbroek AL, Van Ruissen F, Ruijter JM, Baas F.

J Neurosci Res. 2006 Aug 15;84(3):542-52.

PMID:
16786575
14.

Expression profiling of sciatic nerve in a Charcot-Marie-Tooth disease type 1a mouse model.

ten Asbroek AL, Verhamme C, van Groenigen M, Wolterman R, de Kok-Nazaruk MM, Baas F.

J Neurosci Res. 2005 Mar 15;79(6):825-35.

PMID:
15672449
15.

Killing cancer by targeting genes that cancer cells have lost: allele-specific inhibition, a novel approach to the treatment of genetic disorders.

Fluiter K, Housman D, Ten Asbroek AL, Baas F.

Cell Mol Life Sci. 2003 May;60(5):834-43. Review.

PMID:
12827273
16.

In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides.

Fluiter K, ten Asbroek AL, de Wissel MB, Jakobs ME, Wissenbach M, Olsson H, Olsen O, Oerum H, Baas F.

Nucleic Acids Res. 2003 Feb 1;31(3):953-62.

17.

Ribonuclease H1 maps to chromosome 2 and has at least three pseudogene loci in the human genome.

ten Asbroek AL, van Groenigen M, Jakobs ME, Koevoets C, Janssen B, Baas F.

Genomics. 2002 Jun;79(6):818-23.

PMID:
12036296
18.

Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II.

Fluiter K, ten Asbroek AL, van Groenigen M, Nooij M, Aalders MC, Baas F.

Cancer Res. 2002 Apr 1;62(7):2024-8.

19.
20.

Genetic variation in mRNA coding sequences of highly conserved genes.

Ten Asbroek AL, Olsen J, Housman D, Baas F, Stanton V Jr.

Physiol Genomics. 2001 Apr 2;5(3):113-8.

PMID:
11285364
21.

Polymorphisms in the large subunit of human RNA polymerase II as target for allele-specific inhibition.

ten Asbroek AL, Fluiter K, van Groenigen M, Nooij M, Baas F.

Nucleic Acids Res. 2000 Mar 1;28(5):1133-8.

22.

Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor.

Motley AM, Hettema EH, Hogenhout EM, Brites P, ten Asbroek AL, Wijburg FA, Baas F, Heijmans HS, Tabak HF, Wanders RJ, Distel B.

Nat Genet. 1997 Apr;15(4):377-80.

PMID:
9090382
23.

Stable transformation of Trypanosoma brucei.

ten Asbroek AL, Mol CA, Kieft R, Borst P.

Mol Biochem Parasitol. 1993 May;59(1):133-42.

PMID:
8515775
24.

Targeted insertion of the neomycin phosphotransferase gene into the tubulin gene cluster of Trypanosoma brucei.

ten Asbroek AL, Ouellette M, Borst P.

Nature. 1990 Nov 8;348(6297):174-5.

PMID:
2172836
25.

Control of surface antigen genes in African trypanosomes.

Borst P, Gommers-Ampt JH, Lutgerink J, Ouellette M, ten Asbroek AL, Zomerdijk JC.

Biochem Soc Trans. 1990 Oct;18(5):741-2. No abstract available.

PMID:
2083663
26.

The promoter for a variant surface glycoprotein gene expression site in Trypanosoma brucei.

Zomerdijk JC, Ouellette M, ten Asbroek AL, Kieft R, Bommer AM, Clayton CE, Borst P.

EMBO J. 1990 Sep;9(9):2791-801.

27.

Controlled turnover and 3' trimming of the trans splicing precursor of Trypanosoma brucei.

Laird PW, ten Asbroek AL, Borst P.

Nucleic Acids Res. 1987 Dec 23;15(24):10087-103.

Supplemental Content

Loading ...
Support Center